ArticleCureus2024
"Pardon My Language": The Curious Case of a Bloody Sandwich and the John Cunningham Virus Reactivation in the Era of Immunomodulatory Drugs.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive multifocal leukoencephalopathy (PML) is a rare diagnosis associated with high mortality in different clinical settings. PML has been attributed to the reactivation of the John Cunningham (JC) virus (JCV). JCV typically affects patients with HIV/AIDS, solid organ and hematological malignancies, and those under treatment with immunomodulatory drugs (IMiDs) like pomalidomide. Currently, there are a limited number of reported cases of patients with multiple myeloma (MM) who developed PML reported in the literature, and one case report of a patient with MM diagnosed with PML in association with pomalidomide and daratumumab. Here, we describe a case of PML in a patient with MM status post autologous stem cell transplant (ASCT) on maintenance treatment with pomalidomide who presented with cognitive decline and aphasia. In an era of increased access to immunomodulatory therapies, physicians should be able to recognize this potential complication as discontinuation of the medication could be lifesaving.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.